Differences of Therapeutic Efficacy Between Different Kinds of Somatostatin Analogue for Primary Hepatocellular Carcinoma
Abstract
To explore the effects of SOM230, octreotide and lanreotide on hepatocellular carcinoma cell line Bel-7402 In vivoand In vitro, and to analyze the differences of their therapeutic efficacy with relevant mechanisms. Methods At different time points (24, 48, 72 h), the cell counting kit-8 (CCK8) was used to evaluate cell proliferation (drug concentration 1×10-10-1×10-5mol/L) and the Annexin Ⅴ-FITC/PI staining was used to assess cell apoptosis (drug concentration 1×10-5mol/L), while the real-time quantitative PCR was used to detect cellular SSTRexpression changes before and after interventions. A transplanted tumor model was set up, and the tumor-bearing nude mice were treated by three drugs with a common dose of 100 μg/(kg·d) or same volume of normal saline, respectively. After a treatment period of 6 weeks, real-time quantitative PCR and Western blot test were performed to detect the expression changes ofSSTR in tumor tissues from the level of gene and protein. Results All three drugs could inhibit the cell proliferation of Bel-7402. However, they were unable to promote the cell apoptosis. In vitro, the expressions ofSSTR1, SSTR4genes did not change over time in each group. The expressions ofSSTR2gene were decreased in three intervention groups while the expressions ofSSTR5gene were increased first and then decreased. Compared with the control group, all differences have statistical significance (PIn vivo, the expression ofSSTR1gene in SOM230 group was increased when compared with that of the other groups; the expressions ofSSTR2gene in three intervention groups were increased when compared with that of the control group; the expressions of SSTR5gene in SOM230 group and lanreotide group were increased when compared with that of the octreotide group and the control group, and all differences have statistical significance (P<0.05). The Western blot test confirmed these results from the protein level. Conclusion In a certain concentration range, the long-term treatment of SSTA with high affinities to SSTR2 and SSTR5 could inhibit the growth of HCC.
Keywords: Somatostatin, Liver cancer, Bel-7402 cells, Xenografts
Full Text:
PDFReferences
European Association for Study of Liver, European Organization for Research and Treatment of Cancer. EASL- EORTC clinical practice guidelines; management of hepatocellular carcinoma. Eur J Cancer. 2012, 48 (5); 599- 641.
THEODOROPOULOU M, STALLA GK. Somatostatin receptors; from signaling to clinical practice. Front Neuroendocrinol ,2013,34(3); 228-252.
CHALABI M. DULUC C, CARON P, et at. Somatostatin analogs; does pharmacology impact antitumor efficacy, Trends Endocrinol Metab,2014,25(3): 115-127.
HUA YP, YIN XY, PENG BG, et al. Mechanisms and influence of octreotide induced regulation of somatostatin receptor 2 on hepatocellular carcinoma. Chemotherapy ,2009, 55(5):312-320.
SAMONAKISD. NOT AS G, CHRISTODOULAKIS N, et al. Mechanisms of action and resistance of somatostatin analogues for the treatment of hepatocellular carcinoma; a message not well taken. Dig Dis Sci,2008.53(9):2359-2365.
FROIDEVAUX S, HINTEMANN E, TOROK M, et al. Regulation of somatostatin receptor type 2(sst2) expression in AR4-2J tumor cells implanted into mice during octreotide treatment. Cancer Res,l999,59( 15);3652-3657.
BEAUMONT V, HEPWORTH MB. LUTY JS, et al. Somatostatin receptor desensitization in NG108-15 cells; a consequence of receptor sequestration. J Biol Chem, 1998,273 (50):33174-332183.
ABDEL-RAHMAN O, LAMARCA A, VALLE JW. et al. Somatostatin receptor expression in hepatocellular carcinoma: prognostic and therapeutic considerations. Endocr Relat Cancer ,2014,21(6) =4 85-493.
RAI U, THRIMAWITHANA TR, VALERY C, et al. Therapeutic uses of somatostatin and its analogues: current view and potential applications. Pharmacol Ther, 2015, 152 ; 98-110 [ 2016-09-02 ]. http;//www. sciencedirect. com/ science/article/pii/S0163725815000984. doi:10. 1016/j.pharmthera. 2015. 05. 007.
BARBIERI F. BAJETTO A, PATTAROZZI A. et al. Peptide receptor targeting in cancer: the somatostatin paradigm. Int J Pept. 2013. 2013: 926295 [ 2016-09-15 ]. https;//www. ncbi. nlm. nih. gov/pmc/articles/ РМС3582104/. doi: 10. 1155/2013/926295.
Refbacks
- There are currently no refbacks.



